Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02865460 · ClinicalTrials.gov registry record · Phase 3
Coenzyme Q10 Phase III Trial in Gulf War Illness
A Phase 3 study of Gulf War Illness and Chronic Fatigue, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 100
- Enrollment target
- 4
- Study locations
NCT02865460: Completed Phase 3 study of Gulf War Illness and Chronic Fatigue, sponsored by VA Office of Research and Development.
NCT02865460 is a Phase 3 study of Gulf War Illness and Chronic Fatigue that has completed, run by VA Office of Research and Development. The registered enrollment target is 100 participants, below the 123-participant average among 14 other Gulf War Illness trials with a reported enrollment target (19% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02865460, a Phase 3 study of Gulf War Illness and Chronic Fatigue, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 100 participants
- Enrollment target
- 4
- Study locations
Study Summary
The primary objective of this clinical trial is to determine if treatment with ubiquinol, a form of coenzyme Q10, improves the physical function of men and women Veterans suffering from Gulf War Illness (GWI). The primary outcome measure is a change from baseline on the Short Form Health Survey 36-item (SF-36), with respect to physical functioning and symptoms. Secondary outcome measures include changes from baseline levels on GWI-associated biomarkers in peripheral blood and GWI-associated symptoms of chronic pain, fatigue, insomnia, activity level, and cognitive and mental functioning.
Primary Outcome
Veterans Health Survey contains 36 items to measure health functioning from the patient's point of view. The scale is 0-100. The higher value indicates better physical health.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ubiquinol
Study Locations (4)
Florida
- Miami VA Healthcare System, Miami, FL - Miami
Massachusetts
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA - Boston
Minnesota
- Minneapolis VA Health Care System, Minneapolis, MN - Minneapolis
New York
- James J. Peters VA Medical Center, Bronx, NY - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2017-07-24 |
| Est. Completion | 2020-12-31 |
| Phase | Phase 3 |
What the finished NCT02865460 record still lists
NCT02865460 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 123-participant average among 14 other Gulf War Illness trials with a reported enrollment target (19% lower).
The record links to 4 conditions, with Gulf War Illness appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02865460 reports a single indexed study location in Florida, Massachusetts, Minnesota.
Frequently Asked Questions
What is clinical trial NCT02865460 about?
NCT02865460 is a clinical study titled "Coenzyme Q10 Phase III Trial in Gulf War Illness". The primary objective of this clinical trial is to determine if treatment with ubiquinol, a form of coenzyme Q10, improves the physical function of men and women Veterans suffering from Gulf War Illness (GWI). The primary outcome measure is a change from baseline on the Short Form Health Survey 36-i...
What is the current status of trial NCT02865460?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2017-07-24. Estimated completion is 2020-12-31.
What conditions does trial NCT02865460 study?
This clinical trial studies the following conditions: Gulf War Illness, Chronic Fatigue, Ubiquinol, Coenzyme Q10.
What interventions are being tested in trial NCT02865460?
The interventions under investigation include: Placebo (DRUG), Ubiquinol (DRUG).
Who is sponsoring clinical trial NCT02865460?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02865460 being conducted?
This trial has 4 study locations across Florida, Massachusetts, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gulf War Illness
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02865460's enrollment target sits among peer trials
100 6th of 14 higher than 8 of 14 other Gulf War Illness trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gulf War Illness trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Confirmation of Diet as a Treatment for Gulf War Illness
RECRUITING · Phase 3
-
NIH Investigative Deep Phenotyping Study of Gulf War Veteran Health (Project NIH IN-DEPTH)
RECRUITING
-
Validating Gulf War Illness Blood Biomarkers
RECRUITING
-
Nicotinamide Riboside Clinical Trial for GWI
RECRUITING · NA
-
Ca-Mg Butyrate in GWI
RECRUITING · Phase 2
-
Mechanisms of Gulf War Illness
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI